{"id":3029,"date":"2023-06-13T02:09:30","date_gmt":"2023-06-13T02:09:30","guid":{"rendered":"http:\/\/old.nucl-acs.org\/?p=3029"},"modified":"2023-09-26T22:55:12","modified_gmt":"2023-09-26T22:55:12","slug":"post-doc-position","status":"publish","type":"post","link":"https:\/\/old.nucl-acs.org\/?p=3029","title":{"rendered":"Post-Doc Position – Univ of Washington"},"content":{"rendered":"\n

Postdoctoral Scholar in the Radionuclide Production and Molecular Radiotherapy Research Laboratories within the Department of Radiation Oncology at the University of Washington<\/strong>
(https:\/\/radiationoncology.uw.edu\/research\/research-labs\/wilbur-radiochemistry-lab\/<\/a> )<\/p>\n\n\n\n


Position Description:
The Radionuclide Production and Molecular Radiotherapy Research Laboratories in the Department of
Radiation Oncology at the University of Washington (Seattle, WA) is seeking candidates for a Postdoctoral Scholar research position in radionuclide production for molecular radiotherapy. Our research group develops and evaluates radiochemistry methods that can be applied to produce and purify therapeutic and theranostic radionuclides, as well as development of radiolabeling reagents\/chelators used for attaching radionuclides to biological targeting molecules, such as monoclonal antibodies (MAbs) for cancer therapy. Preclinical research in astatine-211-labeled MAbs conducted by our group has been translated to the clinic and is presently being evaluated in multiple human trials.<\/p>\n\n\n\n


The University of Washington Medical Cyclotron Facility is capable of producing variable energy proton,
deuteron, alpha and high energy neutron beams for radionuclide production. The Postdoctoral Scholar in our research group will collaborate with UW Materials Science research groups and cyclotron engineers to develop new target designs for irradiations. It is planned that the candidate will visit and work with our collaborators at National Laboratories and other universities to develop production methods, including purification and radiolabeling, of medical radionuclides. The radiopharmaceuticals under development will be evaluated in animal models through collaborations with investigators in other research groups at the UW and the Fred Hutchinson Cancer Center. The initial appointment is one year, and the appointment is renewable depending upon performance and availability of funding. Anticipated start date is January 1, 2024 or earlier.<\/p>\n\n\n\n

For more information or to apply, please see the attached position advertisement.<\/p>\n\n\n\n